Announcements Trials
Browse Landscape

Phase

Phase 2 58Phase 1 34Phase 3 24Phase 1/2 13Phase NA 12Phase 4 5Phase EARLY_PHASE1 2Phase 2/3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Carcinoma, Non-Small-Cell Lung 10Squamous Cell Carcinoma of Head and Neck 6Stomach Neoplasms 4Prostatic Neoplasms 4Neoplasms 4Lung Neoplasms 4Urinary Bladder Neoplasms 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Oropharyngeal Neoplasms 3Neoplasm Metastasis 3Head and Neck Neoplasms 3Endometrial Neoplasms 3Cholangiocarcinoma 3Breast Neoplasms 3Weight Loss 2Uterine Cervical Neoplasms 2Recurrence 2Myasthenia Gravis 2Mouth Neoplasms 2Melanoma 2Lymphoma, Large B-Cell, Diffuse 2Leukemia, Myeloid, Acute 2Laryngeal Neoplasms 2Hypopharyngeal Neoplasms 2Glioblastoma 2Fallopian Tube Neoplasms 2Colonic Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma 2

Interventions

daratumumab 1Lenalidomide 1Dexamethasone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Multiple Myeloma × 30 days × Clear all
NCT07095452 2026-06-02

A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

AbbVie

Phase 2/3 Recruiting
660 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡